U.S. Markets closed
  • S&P Futures

    4,697.50
    -1.50 (-0.03%)
     
  • Dow Futures

    35,736.00
    -10.00 (-0.03%)
     
  • Nasdaq Futures

    16,382.25
    -10.00 (-0.06%)
     
  • Russell 2000 Futures

    2,268.10
    -1.70 (-0.07%)
     
  • Crude Oil

    72.66
    +0.30 (+0.41%)
     
  • Gold

    1,784.20
    -1.30 (-0.07%)
     
  • Silver

    22.39
    -0.04 (-0.19%)
     
  • EUR/USD

    1.1339
    -0.0005 (-0.0454%)
     
  • 10-Yr Bond

    1.5090
    +0.0290 (+1.96%)
     
  • Vix

    19.90
    -1.99 (-9.09%)
     
  • GBP/USD

    1.3204
    -0.0002 (-0.0185%)
     
  • USD/JPY

    113.7220
    -0.0150 (-0.0132%)
     
  • BTC-USD

    49,792.52
    -743.37 (-1.47%)
     
  • CMC Crypto 200

    1,308.50
    +3.38 (+0.26%)
     
  • FTSE 100

    7,337.05
    -2.85 (-0.04%)
     
  • Nikkei 225

    28,818.94
    -41.68 (-0.14%)
     

Are Insiders Buying Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Stock?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So we'll take a look at whether insiders have been buying or selling shares in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX).

Do Insider Transactions Matter?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, such insiders must disclose their trading activities, and not trade on inside information.

Insider transactions are not the most important thing when it comes to long-term investing. But logic dictates you should pay some attention to whether insiders are buying or selling shares. As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise'.

Check out our latest analysis for Aldeyra Therapeutics

Aldeyra Therapeutics Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when Independent Chair of the Board Richard Douglas bought US$110k worth of shares at a price of US$2.75 per share. We do like to see buying, but this purchase was made at well below the current price of US$6.66. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

Aldeyra Therapeutics insiders may have bought shares in the last year, but they didn't sell any. They paid about US$3.53 on average. We don't deny that it is nice to see insiders buying stock in the company. However, you should keep in mind that they bought when the share price was meaningfully below today's levels. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

Aldeyra Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Does Aldeyra Therapeutics Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Based on our data, Aldeyra Therapeutics insiders have about 1.5% of the stock, worth approximately US$3.9m. We prefer to see high levels of insider ownership.

So What Does This Data Suggest About Aldeyra Therapeutics Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. The transactions are fine but it'd be more encouraging if Aldeyra Therapeutics insiders bought more shares in the company. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 1 warning sign for Aldeyra Therapeutics you should know about.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.